{"id":"W4390963940","doi":"10.1007/s00262-023-03593-2","title":"Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"National Cancer Institute; Sanofi","keywords":"Pembrolizumab; Medicine; Melanoma; Aflibercept; Oncology; Internal medicine; Adverse effect; Immune system; Combination therapy; Immunology; Gastroenterology; Immunotherapy; Cancer research; Bevacizumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006247247,0.0003607456,0.0008740682,0.0002350643,0.0002660476,0.0003250492,0.000208211,0.0003293448,0.0006859027],"category_scores_gemma":[0.0006926899,0.0001939844,0.0003645809,0.0002221284,0.00018575,0.000219243,0.0001228196,0.0005662901,0.0001674526],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003004648,"about_ca_system_score_gemma":0.0002888457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004962187,"about_ca_topic_score_gemma":0.0009320297,"domain_scores_codex":[0.9997821,0.00008744454,0.00001765632,0.00004530535,0.00003168076,0.00003582852],"domain_scores_gemma":[0.9997129,0.00007453206,0.00007663265,0.0000122843,0.00001596247,0.0001076383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.08905684,0.005800748,0.6264181,0.0007099596,0.001150098,0.004047308,0.0007248559,0.001765032,0.1085073,0.0001896308,0.001982789,0.1596474],"study_design_scores_gemma":[0.01550983,0.1158598,0.8391265,0.00009889002,0.001266086,0.01100012,0.0002799818,0.00448291,0.006634271,0.0001702721,0.005531551,0.0000398045],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974573,0.001798889,0.0001145094,0.00007920353,0.00001079522,0.00007080629,0.00004904833,0.000006736821,0.0004126179],"genre_scores_gemma":[0.99889,0.000480462,0.0002591909,0.00009621614,0.00002727502,0.00003031481,0.0001054814,0.000001643798,0.0001095183],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008740682,"threshold_uncertainty_score":0.003303945,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009877809274415455,"score_gpt":0.2785006858800478,"score_spread":0.2686228766056323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}